Core Viewpoint - The report from Citi indicates that the business development (BD) transactions completed by the company are expected to convert into recurring revenue starting this year [1] Group 1: Business Development Transactions - The company has completed four significant BD transactions with AstraZeneca and Madrigal Pharmaceuticals, which are projected to generate approximately $10.2 billion in upfront and milestone payments [1] - These transactions are anticipated to significantly boost the company's profits to 6.3 billion, 10.2 billion, and 10.9 billion from 2025 to 2027 [1] Group 2: Financial Forecast Adjustments - The financial forecasts for 2025 to 2027 have been adjusted, with profit estimates being lowered by 2.4% for 2025, raised by 8.2% for 2026, and increased by 53.7% for 2027, reflecting the financial impact of the BD transactions after risk adjustments [1] Group 3: Investment Rating and Target Price - The company maintains a "highly confident outperform" rating, with the target price raised from HKD 17.4 to HKD 19 [1]
大行评级丨里昂：上调石药集团目标价至19港元，重申“高度确信跑赢大市”评级